Q-omics provides the consensus-scored TSSK6 profile across patient tissues and cancer cell-line models. TSSK6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TSSK6 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TSSK6 RNA expression shows 19,142 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where TSSK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSSK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSSK6 survival associations across molecular data types. TSSK6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSSK6 RNA expression–survival associations across cancer types. High TSSK6 expression shows unfavorable associations in KICH, ACC and LGG, but favorable associations in HNSC, SCLC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TSSK6 RNA expression.
This table summarizes TSSK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TSSK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSSK6 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, COAD, LIHC and KIRC. The HNSC box plot shows higher TSSK6 RNA expression in tumor versus normal tissue (log2 FC = +0.905, t-test p < 0.001).
This table shows molecular features associated with TSSK6 in patient tissues and cancer cell lines. In patient samples, TSSK6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TSSK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
